Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity

This study has been completed.

Study NCT00358293 Information provided by Teva R&D Initiative

First Received: July 27, 2006 Last Updated: January 20, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Study Completion Date:	February 2007
Estimated Primary Completion Date:	No date given